Lonza Rides Biopharma Wave

Lonza has unveiled a robust set of 2006 results, bolstered by a substantial contribution from the company’s fast-growing biopharmaceuticals business. Lonza’s biopharma sales increased 31% last year, to SF468 million ($375 million), the company says. Growing demand and a strong project pipeline supported a number of capacity expansions and related acquisitions in the biopharma field, Lonza says. Lonza’s exclusive synthesis and biopharmaceuticals division, which includes the biopharma business, recorded a 36% increase in 2006 Ebit, to SF193...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers